Imbed Biosciences Inc., a leader in advanced wound care technology, today announced the launch of SAM™ PainGuard™ with Lidocaine, a groundbreaking addition to its acute care portfolio of fully synthetic, antimicrobial, and biocompatible wound matrices. This innovation introduces two new product brands: Surgaflex™ PainGuard™, designed for surgical wounds, and Pelashield™ PainGuard™, tailored for burn and trauma wound management.
This launch highlights the versatility of Imbed’s SAM™ Antimicrobial Technology platform, which uniquely integrates multiple wound care agents into a single matrix composed of bioresorbable polymers. The result is a dual-action solution that delivers both antimicrobial protection and acute pain relief—streamlining wound care and improving patient outcomes.
“Nearly 90% of patients report moderate to severe pain following surgery,” said Terry Bromley, CEO of Imbed Biosciences. “Managing this pain effectively from the start is critical—not only to reduce reliance on systemic pain medications, including opioids, but also to prevent long-term complications such as anxiety, PTSD, and delayed healing, which can be a challenge especially in burn care.”